2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma Growth and Strategic ...

2seventy bio Inc (TSVT) Q3 2024 Earnings Call Highlights: Strong Abecma Growth and Strategic ...

CEO Chip Baird discussed the steady growth in demand for Abecma in the market, driven by increased manufacturing capacity and awareness of its benefits. CFO Vicki Eatwell highlighted improved margins from strong sales and manufacturing success rates, with the break-even point now closer to $300 million.

Read More

Did you find this insightful?